Yersinia secretion apparatus (Ysa), the chromosomal type three secretion system (T3SS) is considered to contribute to virulence of high pathogenicity Yersina enterocolitica biovar 1B. DNAsequence of Ysa pathogenicity island was determined for clinical isolate DM0110 of Y. enterocolitica 1B/O8 with origin in Poland. We found a premature stopcodon in the regulatory gene ysrR (mutation at position 269). 
Yersina enterocolitica is a causative agent of gastro intestinal disorders in humans with a variety of clini cal manifestations, including reactive arthritis and erythema nodosum (Bottone, 1997) . Pathogenic strains of Y. enterocolitica harbour a suit of virulence factors encoded on virulence plasmid pYV and the chromo some. Strains of bioserotype 1B/O8 are considered lethal to mouse and highly pathogenic to humans (Aulisio et al., 1983) . Y. enterocolitica 1B/O8 was origi nally reported in northern America in the 70s and 80s of the past century. In the early 90s bioserotype 1B/O8 disappeared in America and emerged in Japan (Ichinohe et al., 1991) . The first case of human Y. enterocolitica 1B/O8 infection in Europe was reported in Ger many (Schubert et al., 2003) . However, this bacterium is nowadays most numerously isolated in Poland, where 224 human clinical isolates were collected from 2004 to 2013. Y. enterocolitica 1B/O8 isolates collected were tightly clonal (Gierczyński et al., 2009; Zacharczuk, 2012) . The bacterium is an important causative agent of yersiniosis in Poland as shown by serological studies (Rastawicki et al., 2013) .
High pathogenicity of Y. enterocolitica 1B/O8 is attributed to virulence factors encoded in the chromo some. Chromosomal type III protein secretion system (T3SS) named Yersinia secretion apparatus (Ysa) is con sidered a potential virulence factor of the bacterium. Ysa was found to have specific induction conditions -nutrient rich medium supplemented with a high salt concentration (190-400 mM NaCl or KCl) at a moder ate temperature (26-28°C) (Haller et al., 2000, Venecia and Young, 2005) . Therefore, Ysa activity was initially considered as limited to the gastrointestinal tissues. The T3SS was shown to translocate some specific proteins named Yersinia secreted proteins (Ysps) (Haller et al., 2000, Venecia and Young 2005) . Moreover, Ysa was found to secrete some of pYVencoded Yersinia outer proteins (Yops) (Venecia and Young 2005) . In recent studies, Ysa was proposed to act also at the systemic phase of the disease (Bent et al., 2013 Further examinations were performed on a number of 78 clinical isolates and 11 reference strains (Table I) . PFGE typing (data not shown) showed that all the iso lates were tightlyclonal and belonged to the previously described XbaI genotype II (Gierczyński et al., 2009) . Ysa and Ysps proteins were visualised by SDSPAGE assay. The assay was performed in accordance with the procedure described by Matsumoto and Young (2006) . Eight Y. enterocolitica 1B/O8 clinical isolates originat ing in Poland were tested by SDSPAGE together with DM0110 and the 11 reference strains listed in Table I . Bands specific for Ysps and Ysa proteins were detected for the reference strains only. In contrast to the refer ence strain WA314 no Ysps could be detected for clini cal isolate DM0110 in duplicate experiments (Fig. 1A ). Ysps were also lacking in seven randomly selected clini cal isolates (Fig. 1B) .
The YsaPI sequence of DM0110 was aligned to the homologous loci deposited in commonly acces sible databases using CLC Sequence Viewer 7 (CLC Inc, Denmark). Comparison of nucleotide and dedu ced aminoacid sequences of YsaPI of Y. enterocolitica 1B/O8 reference strains: 8081 (NC_008800.1), A127/90 (AF369954.1 and AY100449.2) and WA314 (AKKR01000083) was conducted to trace aminoacid substitutions and other alterations. DM0110 revealed 99% homology to YsaPI of ref erence strains 8081, A127/90 and WA314. No struc tural aberrations were observed. The only significant mutation specific for tested DM0110 was found in ysrR gene that is part of the YsrRST phosphorelay system (Venecia and Young 2005, Walker et al., 2010) . Single nucleotide substitution (C to A) at position 269 of ysrR resulted in a premature stopcodon that terminates translation of YsrR at position 90. No such mutation was found in the reference Y. enterocolitica 1B/O8 strains examined in this study.
To verify whether the stopcodon prematurely ter minates the expression of ysrRin DM0110, the complete ysrR gene (711 bp length) from DM0110 was cloned to expressing vector and examined in Escherichia coli. Expression system pET30 Ek/LIC Vector Kit (Novagen, USA) was used according to the manufacturer's instruc tion. The unaltered ysrR gene from strain WA314 was used as a reference. Laemmli (1970) .The recombinant YsrR protein of DM0110 was about 10 kDa, while the YsrR recombinant of the unal tered ysrR gene from WA314 was 27 kDa. These results confirmed that the premature stopcodon in ysrR is active in vitro. Further analysis in silico performed with Domain Enhanced Lookup Time Accelerated BLAST (DELTABLAST) algorithm showed that YsrR protein REC domain is only halfexpressed in DM0110 while the LuxRClike domain is lacking.
To determine whether other clinical isolates of Y. enterocolitica 1B/O8 in Poland carry unaltered or prematurelyterminated ysrR, PCRRFLP assay target ing the unaltered (wildtype) ysrR gene was developed. Primers (ysrRF 5' ATGACACAAACGAAAACGCT CAAT and ysrRR 5'TTATAGAGAAATTTCATGAG CAT) were used to amplify the 711 bp PCRproduct of the ysrR gene. PCR was conducted as described pre viously (Wołkowicz et al., 2014) . The ysrR PCRprod uct was further digested by BtsI endonuclease (New England BioLabs) as recommended by the manufac turer. The PCRproduct of the unaltered, wildtype ysrR gene yielded two fragments of expected size 268 and 445 bp. In the case of mutation in position 269 of ysrR, the PCRproduct remained undigested. In each PCR RFLP experiment the reference strain WA314 was used as a control for the wildtype ysrR. DM0110 and all the tested clinical isolates listed in Table I were shown by the PCRRFLP assay to bear ysrR gene altered in posi tion specific for the premature stopcodon. No altera tions were detected in ten reference strains of Y. enterocolitica 1B/O8 (Table I ) previously found to secrete Ysps (RokoszChudziak et al., 2013) .
In the past two decades Y. enterocolitica 1B/O8 emerged in Japan, Germany and Poland. Since 2004 this bacterium has been isolated in Poland from humans with clinically confirmed yersiniosis. Noteworthy, all clinical isolates of Y. enterocolitica 1B/O8 in Poland were found to be tightly clonal (Gierczyński et al., 2009 , Zacharczuk, 2013 . Y. enterocolitica 1B/O8 was isolated from a variety of clinical samples including stool and blood. We, therefore, assumed our collections of clini cal isolates constitute an excellent material to study Ysa activity in human yersiniosis.
The results obtained in this study are, however, surprising when compared with other reports on Ysa T3SS published to date (Venecia and Young 2005 , Mat sumoto and Young 2006 , MildinerEarley et al., 2007 , Bent et al., 2013 . First of all we showed that clinical isolates of Y. enterocolitica 1B/O8 collected in Poland from 2004 to 2009 were unable to secrete Ysps. Moreo ver, clinical isolate DM0110 was unable to produce Ysps under a variety of inducible conditions described else where (MildinerEarley et al., 2007 , Witkowski et al., 2008 ) (data not shown). These findings together have prompted us to search YsaPI of DM0110 for possible reasons for Ysa inactivation. One particularly interest ing mutation in the ysrR gene of YsrRST phosphorelay system was detected. This mutation triggers the prema ture stopcodon that early terminates the translation of regulatory gene ysrR. The YsrRST phosphorelay system is considered the major regulatory system for YSAPI (Venecia and Young, 2005, Walker et al., 2010) 
